NEW YORK (GenomeWeb) – BG Medicine said on Wednesday that it has effected a one-for-four reverse stock split to remain listed on the Nasdaq.

The reverse split increases the share price of the company's stock above the minimum $1 bid price to continue listing on the Nasdaq Capital Market. The firm's shares opened at $1.61 per share today after closing at $.43 per share on Wednesday. In early morning trading, the stock rose to $2 per share.

The stock split reduced the number of BG Medicine's common shares outstanding to about 8.6 million shares from about 34.6 million shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.